MAPT and Alzheimer disease: In AD brain homogenate competition assays, it demonstrated a high affinity for tau deposits pIC50 8.4 nM (Table 3), and a superior binding to both 3R and 4R tau aggregate folds in self-competition experiments using recombinant K18 fibrils (representing 4R tau pathology) as well as human PSP and PiD brain homogenates.